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Obesity is a chronic and multifactorial disorder that is reaching epidemic proportions. It
is characterized by an enlarged mass of adipose tissue caused by a combination of size
increase of preexisting adipocytes (hypertrophy) and de novo adipocyte differentiation
(hyperplasia). Obesity is related to many metabolic disorders like hypertension, type
2 diabetes, metabolic syndrome, and cardiovascular disease, and it is associated
with an increased risk of cancer development in different tissues including breast.
Adipose tissue is now regarded as not just a storage reservoir for excess energy, but
rather as an endocrine organ, secreting a large number of bioactive molecules called
adipokines. Among these, adiponectin represents the most abundant adipose tissue-
excreted protein, which exhibits insulin sensitizing, anti-inflammatory, and antiatherogenic
properties. The serum concentrations of adiponectin are inversely correlated with body
mass index. Recently, low levels of plasma adiponectin have been associated with
an increased risk for obesity-related cancers and development of more aggressive
phenotype, concomitantly with alterations in the bioavailability of insulin-like growth factor-
I (IGF-I) and IGF-I receptor (IGF-IR) signaling pathways. In this review, we discuss the
cross-talk between adiponectin/AdipoR1 and IGF-I/IGF-IR in breast cancer.
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Introduction
Breast cancer is one of the most common forms of female malignancy in the world. Many epidemi-
ological studies suggest an important, but still controversial, role for obesity and adipose tissue
mass in breast cancer risk and an association with tumor phenotypes (1). The latter event has
been suggested to relay on the increased estrogen production in peripheral fat deposits, through
the aromatization of androgens, secreted by the adrenal gland (2). However, on the basis of many
recent studies, the contribution of obesity to the development of breast carcinoma cannot be
ascribed to the increased estrogen levels only. In more recent years, it has been demonstrated that
autocrine, endocrine, and paracrine-acting adipocytes-derived factors, known as adipocytokines,
may contribute to the regulation of breast cancer development and progression (3). As a member of
the adipocytokine family, adiponectin is synthesized and secreted almost exclusively by the adipose
tissue (4), and its plasma concentration is inversely correlated with adiposity (5). Adiponectin
exhibits anti-inflammatory activity, a protective effect against metabolic disorders, such as insulin
resistance, fatty-acid oxidation, and insulin sensitivity.
Furthermore, recent clinical studies have implicated that the reduction of circulating adiponectin
levels is a risk factor not only for type 2 diabetes and cardiovascular diseases but also for several types
of cancers, including breast cancer (6, 7). However, conflicting observations have been reported on
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the effects elicited by adiponectin on breast cancer cell growth.
It has been extensively demonstrated that adiponectin induces
an anti-proliferative response in human estrogen receptor alpha
(ERα)-negative breast cancer cells (8–10), while controversial
data are reported in ERα-positive cells (11–16). The possible
mechanisms through which adiponectin exerts anticancer effects
may include activation of AMP-activated kinase and decrease of
mTOR signaling (12). This addresses how a network of different
signaling pathways is involved in the adiponectin-mediated effects
in breast cancer, and the response to adiponectin seems to be
dependent on breast cancer phenotypes.
Obesity and Breast Carcinogenesis
Breast carcinoma represents the highest incidence of cancers
affecting women, and it is the second most fatal cancer type (17,
18). Aside from the genetic predisposition, a myriad of other
factors can contribute to the pathogenesis of breast cancer (19).
Among the modifiable factors, obesity not only represents a seri-
ous risk for breast carcinogenesis but also positively correlated
with a poor outcome (20).
It is now widely accepted that obesity may promote breast
tumor through several mechanisms (Figure 1). Traditionally, the
adverse effect of obesity on breast cancer prognosis has been
linked to the higher estrogen levels produced, consequent to a
greater aromatase activity due to the excess of adipose tissue
(21). Despite the well documented relationship between obesity
and estrogenic activity, it is evident that this cannot fully explain
the association between body weight and breast cancer risk and
prognosis.
Estrogen-independent mechanisms for which there are both
experimental and epidemiological supports involve insulin resis-
tance, hyperinsulinemia, greater bioavailability of insulin-like
growth factor-I (IGF-I), which represents the more relevant
obesity-related growth factor, and dysregulation of insulin-like
growth factor-I receptor (IGF-IR) downstream signaling path-
ways (22).
Apart from these mechanisms, another important element
in obesity-mediated breast carcinogenesis is represented by the
interaction between tumor cells and the surrounding microen-
vironment, which comprises stromal cells, soluble factors, sig-
naling molecules, and extracellular matrix that can promote
tumorigenesis, and make the tumor resistant from host immunity
and therapeutic response. Importantly, obesity is also character-
ized by multiple changes in the adipose tissue biology.
Particularly, white adipose tissue in obese individuals exhibits
chronic mild inflammatory status, mostly defined by infiltra-
tion of leukocytes, including macrophages (23). For instance,
stromal adipocytes directly influence breast cancer cells growth
and progression through the secretion of several biologically
active polypeptides known as adipokines (24, 25), which have a
chemo-attractant action, causing the recruitment ofmacrophages.
The activated macrophages release proinflammatory molecules,
including TNFα, IL-1β, and IL-6. These cytokines play both local
and systemic actions, contributing to insulin resistance and breast
cancer tumorigenesis (26, 27).
Adiponectin
Adiponectin, one of the most important adipokines, is pro-
duced exclusively in white adipocytes. The human gene encoding
adiponectin maps to chromosome 3q27, a region associated with
susceptibility for developing metabolic syndrome and type 2 dia-
betes in Caucasians (28). Adiponectin gene spans 16 kb and con-
tains three exons and two introns (29). Several single nucleotide
polymorphisms (SNPs) in the coding region were identified,
which are associated with alterations of adiponectin function and
important clinical conditions. In particular, SNPs are associated
with the strengthening of adiponectin effects on insulin resistance,
type 2 diabetes, obesity, dyslipidemia, and many obesity-related
malignancies (30).
Structurally, themolecule of human adiponectin consists of 244
amino acid residues and contains four distinct domains; at the N-
terminus, there is an 18 amino acid long-signal peptide followed
by a short-hypervariable region without homology to any known
sequences and a collagen domain with 22 repeated motifs; C-
terminal contains globular domain homologous to C1q molecule
of complement cascade (Figure 2A). The C-terminal globular
domain also shows homology with TNF-α trimeric cytokines
family (31, 32).
Once synthesized, adiponectin undergoes posttranslational
hydroxylation and glycosylation modifications (33) and before
secretion it forms trimers (low-molecular weight, LMW) that
oligomerize to produce hexame-rich middle molecular weight
FIGURE 1 | Relationship between obesity and breast cancer. Principal mechanisms through which the obesity condition may promote breast cancer
development and progression.
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FIGURE 2 | Cross-talk between adiponectin and IGF-IR in breast cancer:
overview of mechanisms. (A) Schematic structure of adiponectin monomer
with different domains and proteolytic cleavage site indicated. fAd and gAd
indicate full length and globular adiponectin, respectively. (B) In ERα-positive
breast cancer cells, adiponectin, produced by adipocytes, binds to AdipoR1,
and establishes cross-talk with membrane ERα and with IGF-IR. The enhanced
phosphorylation of MAPK may allow the activation of IGF-IR, IRS-1, and ERα,
which contribute to breast tumor growth and progression.
(MMW) and high-molecular weight (HMW) forms. Adiponectin
circulating in plasma exists as the full-length protein (fAd) or
a proteolytic cleavage fragment known as globular adiponectin
(gAd) (34–36), which is probably generated by elastase digestion
(37, 38) (Figure 2A).
The levels of this adipokine are abundant in human plasma,
with concentrations ranging from 3 to 30µg/ml (39), and they
are about two to three times lower in male compared to female,
due to the lower amounts of HMW form (40, 41). Its con-
centration is inversely correlated with body mass index (42).
Indeed, unlike most of the other adipokines, plasma adiponectin
levels are found to be lower in obese than in lean individu-
als (3). Moreover, low-circulating levels are found in type 2
diabetes (43), and mice lacking adiponectin develop metabolic
syndrome, with insulin resistance, glucose intolerance, hyper-
glycemia, and hypertension (44, 45). The mechanisms respon-
sible for the adiponectin downregulation are still unclear. It
has been speculated that its reduced levels in obesity may
be caused by the enhanced production of proinflammatory
cytokines, in particular, by the tumor necrosis factor α (TNFα)
(46). However, another potential explanation indicates a negative
feedback of adiponectin on its own production and probably
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on the expression of its receptors during the development of
obesity (47).
Adiponectin Receptors
Adiponectin exerts many of its cellular effects through binding to
two receptor isoforms, the adiponectin receptor 1 (AdipoR1) and
2 (AdipoR2) (48). AdipoR1 and AdipoR2 contain seven trans-
membrane domains with internal N-terminus and external C-
terminus regions; thus, they are both structurally and functionally
distinct fromG-protein-coupled receptors (GPCR) (49). AdipoR1
presents high affinity for gAd and low affinity for the full-size lig-
and (50), and it is expressed ubiquitously but abundantly in skele-
talmuscle and endothelial cells. AdipoR2 has intermediate affinity
for both forms of adiponectin and is predominantly expressed
in the liver (51). Since AdipoR1 is the predominant receptor
in skeletal muscle, while AdipoR2 is predominantly expressed
in liver, this correlated with the fact that gAd exerts its insulin
mimetic and insulin-sensitizing effect more effectively compared
to fAd in skeletal muscle and vice versa (52).
A non-classical third potential adiponectin receptor is T-
cadherin, which was also found to competitively bind only the
hexameric andHMWforms of adiponectin (53–55). Various stud-
ies have suggested the involvement of T-cadherin, which plays
an important role in cell adhesion and in calcium-mediated cell
to cell interactions and signaling (53), in mediating functional
effects of adiponectin. T-cadherin lacks an intracellular domain
needed for signal transduction; thus, it has been suggested that
it may function as a coreceptor by competing with AdipoR1 and
AdipoR2 receptors for adiponectin binding or interfering with
adiponectin signal transduction (56).
Adiponectin Signaling Pathways
Adiponectin activates various signaling molecules when bound to
its receptors. Several adiponectin receptor binding proteins have
now been identified (57). Among these, the first and best char-
acterized is the adaptor protein APPL1, containing a pleckstrin
homology domain, a phosphotyrosine binding (PTB) domain,
and a leucine zippermotif (57, 58). AdipoR1 andAdipoR2 interact
with the PTB domain of APPL-1 through their N-terminal intra-
cellular region, thereby inducing adiponectin actions through the
sequential activation of downstream signaling. It has emerged that
APPL1 plays an important role inmediatingmany of adiponectin’s
effects, including metabolic, antiinflammation, antiatherogenic,
and cytoprotection responses (59, 60).
Adiponectin exerts its effects through the activation of AMPK,
mTOR, PI3K/Akt, MAPK, PPAR-α, STAT3, and NF-kB (47, 59).
Most of its effects aremediated through the cellular energy sen-
sorAMPK (61, 62), which promotes glucose utilization that results
in an increased fatty-acid oxidation, increased glucose uptake
at the skeletal muscle level, and reduced gluconeogenesis in the
liver (47). In addition, adiponectin exerts its insulin-sensitizing
effects through the activation of PPAR-α, thereby enhancing fatty-
acid combustion and energy consumption, leading to a tissue
decrease content of triglycerides in the liver and skeletal muscle,
and improving insulin sensitivity in vivo (63).
Adiponectin and Breast Cancer
Adiponectin is emerging as an important factor in carcinogene-
sis. Many clinical investigations suggested that low-adiponectin
concentrations are associated with an increased risk for obesity-
related cancer, such as prostate, colon, endometrial, and breast
cancer (47). Epidemiological studies address that, in women with
low-circulating adiponectin levels, breast tumors may present a
more aggressive phenotype, exemplified by large tumor size, high-
histological grade, estrogen receptor negativity, and increased
angiogenesis and metastasis (6). Recently, through a transcrip-
tomic profiling, Merdad and co-workers evidenced a downreg-
ulation of adiponectin and other molecules involved in lipid
metabolism in surgically resected breast tumors patients. The
results address how some ethnic groups are more susceptible to
breast cancer occurrence (64).
It has beenwell documented that the pathogenesis ofmammary
cancer is not only dependent on genetic alterations but also largely
on the interactions between malignant cells and components of
the breast microenvironment, which exerts an important influ-
ence on the phenotype of the neoplastic cells and on tumor
progression.Microenvironmentalmolecules, such as chemokines,
cytokines, and growth factors, could influence tumor progression
by three major, non-mutually exclusive, mechanisms. The first is
by further increasing the genetic instability of tumor cells. The
second is by inducing signaling cascades in tumor cells via tumor-
associated receptors thereby controlling gene expression in these
cells. The third mechanism is by exerting selective pressures on
the cells (24, 65).
Thus, the malignant cell phenotype is regulated not only by
autonomous signals originating from cancer cells but also by the
effects of the surrounding stromal cells, which influence mam-
mary epithelial cell growth and differentiation (24). The close
association betweenmammary epithelial cells and adipocytesmay
favor a more direct action of adipokines on such tissue (11).
However, the role of this adipokine on breast tumorigene-
sis is still unclear, and it seems to be dependent on cell types.
Low-adiponectin doses mediate an anti-proliferative response in
ERα-negative breast cancer cells through the regulation of genes
involved in cell cycle, such as p53, Bax, Bcl-2, c-myc, and Cyclin
D1 (66). In addition, in these cells, the adipokine is able to acti-
vate the AMPK, which in turn inhibits mTOR, through tuberous
sclerosis complex 2 (TSC2), thus counteracting carcinogenesis
(67, 68). Moreover, activated AMPK plays a crucial role in the
regulation of growth arrest and apoptosis by stimulating p21 and
p53 (69). On the other hand, it is emerging that adiponectin, at
low concentrations, increases proliferation in ERα-positive breast
cancer cells (15, 16). This occurs through the activation of ERα
at both genomic and non-genomic levels (70), together with the
positive regulation of cyclin D1 expression (71).
On the basis of these observations, adiponectinmay represent a
promising diagnostic and prognostic biomarker to identify high-
susceptibility individuals for developing obesity-related tumors.
Recently, it has developed an adiponectin-based short peptide,
ADP 355, acting as AdipoR1 agonist, and able to modulate
several signaling pathways (AMPK, Akt, STAT3, and ERK1/2) in a
manner similar to gAd. In breast cancer cells, ADP 355 reproduces
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the adiponectin-induced anti-proliferative activity both in vitro
and in vivo (3, 72, 73).
IGF-IR in Breast Cancer
Insulin-like growth factor-I receptor is an evolutionary conserved,
ubiquitous transmembrane tyrosine kinase structurally similar to
the insulin receptor. IGF-IR regulates different biological pro-
cesses, such as proliferation, survival, differentiation, transfor-
mation, cell-substrate, and cell–cell interactions (74–79). More
recently, it has been highlighted that the role of the IGF-IR in
the development and maintenance of the cancer stem cells, in
epithelial–mesenchymal transition, and in the regulation of the
tumor microenvironment (80). The first evidence that IGF-IR is
critical in tumorigenesis was provided by the observation that
constitutive overexpression of IGF-IR induced the transformed
phenotype in cultured cells (81, 82).
It is now quite evident that IGF-IR plays a multifaceted and
complex role in the development and progression of a malignant
disease. Numerous clinical and experimental data indicated that
IGF-IR is overexpressed in several subtypes of breast cancer (83),
and many conditions lead to the activation of IGF-IR tyrosine
kinase activity (84), allowing interaction with its main substrates,
such as insulin receptor substrates (IRS) and the Src-homology-2-
containing protein SH2 (SHC) (74). Once phosphorylated, these
proteins act as docking molecules that bind to and activate cel-
lular kinases, initiating different downstream signaling pathways.
In this regard, IGF-IR induces activation of Ras/raf/MAPK and
PI3K/Akt signaling, which alter the expression of genes involved
in cell proliferation and survival (85), thus contributing to breast
carcinogenesis.
In hormone-dependent breast cancer cells, the IGF-IR and
ERα are co-expressed and IGF-I acts in synergy with estradiol to
stimulate proliferation (74). Indeed, estradiol up-regulates IGF-IR
mRNA and protein levels as well as its tyrosine phosphorylation
(73, 74, 86). Furthermore, estradiol significantly stimulates the
expression of IRS-1 in ERα-positive cells (87).
Elevated expression of IGF-IR or IRS-1 appears to increase
drug and radio resistance of breast cancer cells and favor cancer
recurrence in patients (88, 89). In addition to promote cell growth,
IGF-IR counteracts apoptosis in ERα-positive cells, activating the
IRS-1/PI3K pathway (74, 89). For these reasons, IGF axis has been
validated for developing targeted therapy for cancer prevention
and treatment (80, 90, 91).
Adiponectin and IGF-IR Interaction
in Breast Cancer
Insulin-like growth factors and IGF-IR are involved in the
metabolic cellular response to adiponectin inmany cell types (63).
It has beenwidely demonstrated that IGF-IR increases growth and
survival of neoplastic cells, altering the expression of specific genes
regulated through the activation of Akt andMAPK pathways (92).
Emerging evidences address the existence of a cross-talk
between adiponectin/AdipoR1 and IGF-IR in breast cancer. It has
been previously demonstrated that adiponectin increases IGF-IR-
β subunit tyrosine phosphorylation and the downstream MAPK
activation in granulosa cells (93). More recently, it has been
shown that low concentrations of adiponectin rapidly increase
IGF-IR phosphorylation in ERα-positive breast cancer cells, con-
comitantly with ligand-independent activation of ERα (70). It is
worth to note that in MCF-7 cells, upon adiponectin treatment,
knockdown of ERα reduces IGF-IR phosphorylation, whereas
a specific siRNA for IGF-IR prevents adiponectin-induced ERα
transactivation (70).
Moreover, IGF-IR takes part in the formation of a protein
complex involved in the induction of ERα-positive breast cancer
cell growth. Indeed, adiponectin enhances the coimmunoprecipi-
tation ofAdipoR1,APPL1, ERα, IGF-IR, and c-Src inMCF-7 cells.
The formation of this multiprotein complex leads, via c-Src, to
MAPK activation, which is abrogated in the presence of specific
RNA silencers targeting ERα or IGF-IR (70). On the other hand,
in ERα-negative MDA-MB-231 cells adiponectin is no longer
able to induce MAPK phosphorylation, but it increases activation
of AMPK, which mediates anti-proliferative effect in these cells
(70, 71). In this concern, it has been well documented how in
breast cancer cells the adiponectin-induced activation of AMPK
is concomitant with inactivation of MAPK (12).
Interestingly, our unpublished data demonstrate that
adiponectin enhances phosphorylation and protein expression of
IRS-1 inERα-positive breast cancer cells, thus amplifying the IGF-
I/IGF-IR growth signaling. All these data address the existence
of a possible cross-talk between Adiponectin/AdipoR1, ERα, and
IGF-IR involved in the positive regulation of ERα-positive breast
cancer cell growth. These data are supported by other papers
showing that adiponectin, via its adapter protein APPL1, is able
to induce phosphorylation of IRS-1, which mediates the effect of
activated IR/IGF-IR in normal and tumoral cells (63, 94).
Our preliminary results surprisingly show that adiponectin at
low concentrations is able to potentiate IGF-I-induced anchorage-
independent growth in ERα-positive breast cancer cells. In con-
trast, adiponectin is able to elicit opposite action in antagonizing
the stimulatory effects induced by IGF-I in ERα-negative breast
cancer cells. In the same vein, wound healing assays evidence
that in ERα-positive breast cancer cells, adiponectin, and IGF-I
enhance cell motility and the co-treatment results in an addi-
tive effect, addressing how adiponectin may synergize with IGF-
IR signaling. On the contrary, in ERα-negative breast cancer
cells adiponectin counteracts the IGF-I-induced cell migration
(manuscript in preparation). These results well fit with recent
findings demonstrating that adiponectin is able to regulate migra-
tion and invasion in different breast cancer cells (95–97).
Conclusion
Adiponectin is emerging as a crucial adipokine involved in
breast carcinogenesis in women with obesity. In ERα-positive
breast cancer cells, the interaction of adiponectin with its
specific receptor induces the activation of multiple pathways,
through the interplay between ERα and IGF-IR. This leads to
(i) increased activation of MAPK and upregulation of genes
involved in proliferation and inhibition of apoptosis, (ii) induction
of cell migration (Figure 2B). On the basis of these findings,
we may conclude that adiponectin differently modulates IGF-I
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stimulatory effect in breast cancer cells in relationship to ERα
status. Indeed, the antagonistic effects exerted by adiponectin on
IGF-IR signaling are evident only in ERα-negative breast cancer
cells. Thus, only in the latter circumstance, adiponectin sounds
to be exploited in novel therapeutic strategies for breast cancer
treatment.
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